Barriers to effective treatment of vaginal atrophy with local estrogen therapy

International Journal of General Medicine

Volumn 6, Issue , 2013, Pages 153-158

  Reiter, Suzanne ^a  

^a Mid County Health Center   (United States)

Author keywords

Barriers; Local estrogen therapy; Postmenopausal women; Vaginal atrophy

Indexed keywords

ESTRADIOL; ESTROGEN;

CLINICAL FEATURE; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PATIENT ATTITUDE; PATIENT COUNSELING; PATIENT EDUCATION; PELVIC EXAMINATION; PERCEPTION; PH MEASUREMENT; PHYSICIAN ATTITUDE; POSTMENOPAUSE; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; REVIEW; VAGINA ATROPHY; VERBAL COMMUNICATION;

EID: 84875284598     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S43192     Document Type: Review

References (28)

1. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133-2142.
2. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233-238.
3. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3):357-369.
4. Sturdee DW, Panay N. On behalf of the International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6): 509-522.
5. Stika CS. Atrophic vaginitis. Dermatol Ther. 2010;23(5):514-522.
6. MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94.
7. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol. 2008;112(5):1053-1060.
8. Wyeth. REVEAL REvealing Vaginal Effects At mid-Life: Surveys of postmenopausal women and health care professionals who treat postmenopausal women. Madison, NJ: Wyeth; 2009. Available from: http://www.revealsurvey.com/pdf/reveal-survey-results.pdf. Accessed February 21, 2013.
9. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views and Attitudes (VIVA) - results from an international survey. Climacteric. 2012;15(1):36-44.
10. Prickett KC, Angel JL. The new health care law: how will women near retirement fare? Womens Health Issues. 2011;21(5):331-337.
11. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril. 1994;61(1):178-180.
12. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(3):259-263.
13. Andelloux M. Products for sexual lubrication: understanding and addressing options with your patients. Nurs Womens Health. 2011; 15(3):253-257.
14. The North American Menopause Society. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2012;19(3):257-271.
15. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;4:CD001500.
16. Estrace™ (estradiol vaginal cream, USP, 0.01%, prescribing information). Rockaway, NJ: Warner Chilcott; 2011.
17. Premarin™ (conjugated estrogen, vaginal cream, prescribing information). Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2010.
18. Estring™ (estradiol vaginal ring, prescribing information). New York, NY: Pharmacia and Upjohn Company; 2008.
19. Vagifem™ (estradiol vaginal tablets, prescribing information). Princeton, NJ: Novo Nordisk Inc; 2009.
20. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010;116(4):876-883.
21. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005;8(1):83-92.
22. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause. 2009;16(4):719-727.
23. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets. Climacteric. 2010;13(3):219-227.
24. Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab. 2006;91(10):3791-3797.
25. Santen RJ, Demers L, Ohorodnik S, et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids. 2007; 72(8):666-671.
26. Cano A, Estevez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause. 2012;19(10): 1130-1139.
27. Cumming GP, Currie HD, Moncur R, Lee AJ. Web-based survey on the effect of menopause on women's libido in a computer-literate population. Menopause Int. 2009;15(1):8-12.
28. Panay N, Maamari R. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets. Menopause Int. 2012;18(1): 15-19.